Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of CIT-013 in moderate to severe hidradenitis suppurativa
NL-OMON60843Phase 2Active, not recruiting
- Sponsor
- Citryll
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CIT013 in hidradenitis suppurativa (HS) (3 arms), sponsored by Citryll. Primary endpoint: HiSCR75 response at Day 85. Started Jan 2026; status: active, not recruiting.
02
Drugs
CIT013
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON60843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60843.